Prevention of cardiotoxicity among survivors of childhood cancer

Kelley K. Hutchins, Hani Siddeek, Vivian I. Franco, Steven E Lipshultz

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

The number of survivors of childhood cancers has increased exponentially over the past few decades. However, these survivors are also at substantially increased long-term risk of morbidity and mortality, especially from treatment-related cardiotoxicity. Preventing these risks is now a priority when treating children and adolescents with cancer. Dexrazoxane reduces the risk of anthracycline-induced cardiotoxicity among adults and children with cancer without reducing its antineoplastic effects or event-free survival. Thus, it should be strongly considered as a part of therapy for children and adolescents treated with anthracyclines.

Original languageEnglish (US)
JournalBritish Journal of Clinical Pharmacology
DOIs
StateAccepted/In press - 2016
Externally publishedYes

Keywords

  • Cardiotoxicity
  • Childhood cancer
  • Dexrazoxane
  • Survivor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Prevention of cardiotoxicity among survivors of childhood cancer'. Together they form a unique fingerprint.

  • Cite this